食管癌--X线钡餐-CT病例图片影像诊断分析

2022-09-06 华夏影像诊断中心 网络

食管癌是消化系统常见恶性肿瘤之一,好发于40岁以上,男性多见。临床上主要表现为进行性吞咽困难。病变部位:中段>下段>上段。病理上以鳞癌为多。食管癌可分为早期食管癌和中晚期食管癌。

【病史临床】男,63岁,胸痛,进行性吞咽困难伴消瘦20天。

【影像图片】

【影像表现】 CT:表现现为食管壁明显增厚,管腔狭窄;食管与周围结构分界不清食管吞钡:食管中段充盈缺损,管腔不规则狭窄,管壁僵硬,粘膜纠集破坏,与正常食管壁分界清晰。

【诊断】 病理诊断:食管(中下段)高-中分化鳞状细胞癌,侵及食管壁全层。(图1.2)

【鉴别诊断】

1.食管良性肿瘤(平滑肌瘤)

2.食管贲门失迟缓症

3.胃食管反流病

4.食管静脉曲张

【讨论】 食管癌是消化系统常见恶性肿瘤之一,好发于40岁以上,男性多见。临床上主要表现为进行性吞咽困难。病变部位:中段>下段>上段。病理上以鳞癌为多。食管癌可分为早期食管癌和中晚期食管癌,早期食管癌可分为隐匿型、糜烂型、斑块型和乳头状型。中晚期癌可分为5型,髓质型:呈坡状隆起,侵及食管壁各层及周围组织,本型多见,恶性程度较高。蕈伞型:多呈圆形或卵圆形,向食管腔内突起,边缘外翻如蕈伞状,表面常有溃疡,属高分化癌,预后较好。溃疡型:表面常有较深的溃疡,边缘稍隆起,出血和转移较早,梗阻发生较晚。缩窄型:环形生长,质硬,侵入食管全周,食管粘膜呈向心性收缩,梗阻发生较早,转移发生较晚,本型少见。其他类型:不能归入上述各型的。

影像学诊断要点:内镜检查并活检是诊断食管癌首选的方法。内镜下食管粘膜染色有助于提高早期食管癌的检出率。X线检查:早期食管癌:病变区黏膜皱襞增粗紊乱,中断及扭曲;小凹陷或隆起性病变,直径约<5mm,管壁轻度僵硬,扩张伸展稍受限。可形成溃疡,呈地图状。病变常累及周径于局部,与正常管径分界截然。进展期:蕈伞型:管腔内菜花样或蕈伞样充盈缺损,偏于食管一侧,范围较大,可见不同程度梗阻。溃疡型:纵形腔外龛影,龛影可见尖角征,周边可见环堤(周围肿瘤组织呈带状密度减低区)。浸润型:局限性环形狭窄,轮廓毛糙,与正常食管分界清楚,钡剂通过缓慢,近端不同程度扩张。髓质型:广泛侵犯食管全层,形成腔外肿物,管腔狭窄,表面可见溃疡。混合型:以上多种表现均可存在。CT:食管壁环形或不规则增厚,厚度>5mm应视为异常;或形成腔内肿块,多为广基底,表面有时可见龛影;食管周围脂肪层模糊、消失;周围器官受累或(和)淋巴结转移;增强扫描可见肿块轻度强化,较大瘤体强化不均匀,可合并低密度坏死灶。MRI:扫描前需嘱咐病人吞服适量液体。中晚期食管癌表现为信号异常,T1WI与肌肉信号近似,T2WI较肌肉信号高,增强扫描病灶明显强化。

与食管贲门失弛缓症相鉴别:后者多见于20~40岁女性,临床上表现为间歇性吞咽困难,病程较长,典型X线钡餐表现为漏斗状或鸟嘴样梗阻,管壁柔软,边缘光滑,粘膜正常,食管上段明显扩张。服用硝酸甘油类药物可缓解症状。

与胃食管反流病相鉴别:后者影像学无新生物,仅表现为粘膜炎症、溃疡或糜烂。

与食管静脉曲张相鉴别:后者常有肝硬化、门脉高压病史,食管壁柔软,粘膜正常,CT增强扫描可见明显强化的迂曲血管团,呈持续、延迟性强化。MRI:由于流空效应,曲张的血管在T1WI及T2WI上均呈低信号,增强扫描静脉期病灶明显强化。CT三维重建及MRI血管重建可以清晰显示曲张血管的全貌。

与食管平滑肌瘤相鉴别:后者表现为腔内光滑圆形充盈缺损,无管壁僵硬、黏膜皱襞破坏、周围组织侵犯及转移等恶性肿瘤征象。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783898, encodeId=90341e838983b, content=<a href='/topic/show?id=947f54e23d' target=_blank style='color:#2F92EE;'>#CT病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5472, encryptionId=947f54e23d, topicName=CT病例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Mar 23 09:43:26 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298097, encodeId=ac29129809ec9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437781, encodeId=be9d143e781a1, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445665, encodeId=8d401445665b5, content=<a href='/topic/show?id=643e5031124' target=_blank style='color:#2F92EE;'>#影像诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50311, encryptionId=643e5031124, topicName=影像诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erGh2JQt8g9L1dqpdLyJ7EDClYbBfjvngmKJ6Vn8jCDHuYvHH6ZLao7bSXVr4okhjNU9ojr0SZFxQ/132, createdBy=12ec5143276, createdName=12498fa0m12暂无昵称, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1783898, encodeId=90341e838983b, content=<a href='/topic/show?id=947f54e23d' target=_blank style='color:#2F92EE;'>#CT病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5472, encryptionId=947f54e23d, topicName=CT病例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Mar 23 09:43:26 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298097, encodeId=ac29129809ec9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437781, encodeId=be9d143e781a1, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445665, encodeId=8d401445665b5, content=<a href='/topic/show?id=643e5031124' target=_blank style='color:#2F92EE;'>#影像诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50311, encryptionId=643e5031124, topicName=影像诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erGh2JQt8g9L1dqpdLyJ7EDClYbBfjvngmKJ6Vn8jCDHuYvHH6ZLao7bSXVr4okhjNU9ojr0SZFxQ/132, createdBy=12ec5143276, createdName=12498fa0m12暂无昵称, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2021-11-07 piaojinhua
  3. [GetPortalCommentsPageByObjectIdResponse(id=1783898, encodeId=90341e838983b, content=<a href='/topic/show?id=947f54e23d' target=_blank style='color:#2F92EE;'>#CT病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5472, encryptionId=947f54e23d, topicName=CT病例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Mar 23 09:43:26 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298097, encodeId=ac29129809ec9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437781, encodeId=be9d143e781a1, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445665, encodeId=8d401445665b5, content=<a href='/topic/show?id=643e5031124' target=_blank style='color:#2F92EE;'>#影像诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50311, encryptionId=643e5031124, topicName=影像诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erGh2JQt8g9L1dqpdLyJ7EDClYbBfjvngmKJ6Vn8jCDHuYvHH6ZLao7bSXVr4okhjNU9ojr0SZFxQ/132, createdBy=12ec5143276, createdName=12498fa0m12暂无昵称, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1783898, encodeId=90341e838983b, content=<a href='/topic/show?id=947f54e23d' target=_blank style='color:#2F92EE;'>#CT病例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5472, encryptionId=947f54e23d, topicName=CT病例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Mar 23 09:43:26 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298097, encodeId=ac29129809ec9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437781, encodeId=be9d143e781a1, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445665, encodeId=8d401445665b5, content=<a href='/topic/show?id=643e5031124' target=_blank style='color:#2F92EE;'>#影像诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50311, encryptionId=643e5031124, topicName=影像诊断)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erGh2JQt8g9L1dqpdLyJ7EDClYbBfjvngmKJ6Vn8jCDHuYvHH6ZLao7bSXVr4okhjNU9ojr0SZFxQ/132, createdBy=12ec5143276, createdName=12498fa0m12暂无昵称, createdTime=Sun Nov 07 09:43:26 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

相关资讯

Gastroenterology:颠覆!T1bN0M期食管鳞癌患者采用放化疗治疗的效果不劣于手术!

对于 T1bN0M0 期 ESCC 患者,联合放化疗的效果不劣于手术,可考虑作为这类患者的治疗方案

君实生物特瑞普利单抗治疗食管癌获得美国FDA孤儿药资格认定

君实生物自主研发的抗PD-1单抗药物特瑞普利单抗用于治疗食管癌(EC)获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定(Orphan-drug Designation)。

许树长:3天入门实战训练营——食管疾病的内镜诊治

许树长:3天入门实战训练营——食管疾病的内镜诊治

ESMO 2021:特瑞普利单抗一线治疗食管癌的Ⅲ期临床研究结果公布,OS高达17个月

2021年9月16日至21日,2021年欧洲肿瘤内科学会(ESMO)年会采用线上会议的方式举行。作为全球最具影响力的肿瘤学术平台之一,ESMO年会每年都会汇聚全球肿瘤专业人士,共同分享肿瘤领域的前沿研

JAMA |我国学者:卡瑞丽珠单抗降低晚期食管癌患者3成生存率、4成无进展生存!

在晚期或转移性食管鳞状细胞癌患者中,在化疗的基础上加用卡瑞丽珠可显著改善总生存期和无进展生存期。

中国已成癌症大国!肺癌死亡率飙升4倍,男性高于女性​

此次2020年的《全球癌症统计报告》 共涵盖全球185个国家、36种癌症。其主要内容包括6大部分:全球癌症分布、主要致癌因素、癌症的病理过程、社会因素对于癌症预防的影响、常见癌症的预防策略及其理论基础